Epratuzumab

Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases[1].

Product Specifications

CAS Number

[205923-57-5]

Product Name Alternative

Antibody hLL 2; AMG-412

UNSPSC

12352203

Target

CD22

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/epratuzumab.html

Purity

99.53

Solubility

10 mM in DMSO

Smiles

[Epratuzumab]

Molecular Weight

(146.58 kDa)

References & Citations

[1]Carnahan J, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res. 2003 Sep 1;9 (10 Pt 2) :3982S-90S.